ValoreQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMSpese di vendita, generali e amministrative32.44 M29.01 M27.21 M30.51 M33.08 M119.8 MRicerca e sviluppo116.88 M108.43 M97.03 M94.75 M88.65 M388.86 MReddito operativo-136.45 M-120.81 M-110 M-111.48 M-98.71 M-440.99 MProventi non operativi, Totale15.1 M12.96 M17.48 M20.31 M5.85 M56.59 MOneri finanziari, al netto degli interessi capitalizzati——————Proventi non operativi, esclusi gli oneri finanziari7.55 M6.48 M8.74 M10.15 M2.92 M28.3 MEntrate/uscite straordinarie7.55 M6.48 M8.74 M10.15 M2.92 M28.3 MUtile al lordo delle imposte-121.35 M-107.85 M-92.51 M-91.17 M-92.86 M-384.4 MQuota di utile0———0—Imposte————45.77 M—Interessi di minoranza——————Altri proventi/oneri al netto delle imposte——————Utile netto al lordo delle attività cessate-128.9 M-114.33 M-101.25 M-101.32 M-95.79 M-412.69 MAttività cessate——————Utile netto-128.9 M-114.33 M-101.25 M-101.32 M-95.79 M-412.69 MRegolazione della diluizione——————Dividendi privilegiati——————Utile netto diluito attribuibile agli azionisti ordinari-128.9 M-114.33 M-101.25 M-101.32 M-95.79 M-412.69 MUtile base per azione (EPS base)-1.27-1.1-0.98-0.92-0.81-3.81Utile diluito per azione (EPS diluito)-1.27-1.1-0.98-0.92-0.81-3.81Numero medio di azioni ordinarie in circolazione98.85 M103.5 M103.73 M110.19 M108.38 M425.8 MAzioni diluite in circolazione98.85 M103.5 M103.73 M110.19 M108.38 M425.8 MEBITDA-133.87 M-118.31 M-107.5 M-109.08 M-96.34 M-431.22 MEBIT-136.45 M-120.81 M-110 M-111.48 M-98.71 M-440.99 MCosto del fatturato——————Altri costi del venduto——————Ammortamento e svalutazione (liquidità)2.57 M2.5 M2.5 M2.4 M2.37 M9.77 M
Intellia Therapeutics Inc
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies.